Linyong Xu

1.0k total citations
35 papers, 740 citations indexed

About

Linyong Xu is a scholar working on Molecular Biology, Oncology and Epidemiology. According to data from OpenAlex, Linyong Xu has authored 35 papers receiving a total of 740 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 6 papers in Oncology and 6 papers in Epidemiology. Recurrent topics in Linyong Xu's work include Drug Transport and Resistance Mechanisms (5 papers), Pharmacological Effects and Toxicity Studies (4 papers) and SARS-CoV-2 and COVID-19 Research (2 papers). Linyong Xu is often cited by papers focused on Drug Transport and Resistance Mechanisms (5 papers), Pharmacological Effects and Toxicity Studies (4 papers) and SARS-CoV-2 and COVID-19 Research (2 papers). Linyong Xu collaborates with scholars based in China, United States and Switzerland. Linyong Xu's co-authors include Mingyi Zhao, Quan Zhuang, Xinyu Li, Qingnan He, Yijing He, Zeyu Wang, Wei Zhang, Gan Zhou, Wei Zhang and Sheng Deng and has published in prestigious journals such as PLoS ONE, Information & Management and World Journal of Gastroenterology.

In The Last Decade

Linyong Xu

34 papers receiving 735 citations

Peers

Countries citing papers authored by Linyong Xu

Since Specialization

Citations

This map shows the geographic impact of Linyong Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Linyong Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Linyong Xu more than expected).

Fields of papers citing papers by Linyong Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Linyong Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Linyong Xu. The network helps show where Linyong Xu may publish in the future.

Co-authorship network of co-authors of Linyong Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Linyong Xu. A scholar is included among the top collaborators of Linyong Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Linyong Xu. Linyong Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Early detection of Parkinson’s disease through multiplex blood and urine biomarkers prior to clinical diagnosis 2025 ·npj Parkinson s Disease ·Shuo Gao, Zheng Wang, (unknown), Guang Yang, (unknown), (unknown), Qiao Zhou, Xingxing Jian, Guihu Zhao, Bin Li, Linyong Xu, Kun Xia, Beisha Tang, Jinchen Li	2
2	Identification of the shared genes and immune signatures between systemic lupus erythematosus and idiopathic pulmonary fibrosis 2023 ·Hereditas ·(unknown), (unknown), Ying Zhang, (unknown), Linyong Xu, Quan Zhuang	1
3	Identification and validation of an immunological microenvironment signature and prediction model for epstein-barr virus positive lymphoma: Implications for immunotherapy 2022 ·Frontiers in Oncology ·(unknown), Ruoyao Xu, Qianyuan Li, Sheng Xiao, Min Hu, Linyong Xu, Quan Zhuang	2
4	Discrete simulation analysis of COVID-19 and prediction of isolation bed numbers 2021 ·PeerJ ·Xinyu Li, Yufeng Cai, (unknown), Jia‐Da Li, Guoqing Huang, Liang Ye, Linyong Xu	1
5	Aligning Estimators With Estimands in Clinical Trials: Putting the ICH E9(R1) Guidelines Into Practice 2020 ·Therapeutic Innovation & Regulatory Science ·Craig Mallinckrodt, (unknown), (unknown), Bohdana Ratitch, Michael O’Kelly, Ilya Lipkovich, Pritibha Singh, Linyong Xu, Geert Molenberghs	42
6	Oxygen homeostasis and cardiovascular disease: A role for HIF? 2020 ·Biomedicine & Pharmacotherapy ·Xinyu Li, (unknown), (unknown), Linyong Xu, Xueyan Zhang, Ping Zhu, Qingnan He, Mingyi Zhao	34
7	Aligning Estimators With Estimands in Clinical Trials: Putting the ICH E9(R1) Guidelines Into Practice 2019 ·Therapeutic Innovation & Regulatory Science ·Craig Mallinckrodt, (unknown), (unknown), Bohdana Ratitch, Michael O’Kelly, Ilya Lipkovich, Pritibha Singh, Linyong Xu, Geert Molenberghs	7
8	Roles of pyroptosis in myocardial ischemia/reperfusion injury diseases 2019 ·Wenzhe Gao, Jie Shen, Feng Guo, Mingyi Zhao, Linyong Xu, Haoran Zhang, Moussa Ide Nasser, Yanyang Tu, Minghua Yang, (unknown)	1
9	Extracellular HMGB1 prevents necroptosis in acute myeloid leukemia cells 2019 ·Biomedicine & Pharmacotherapy ·Yingting Liu, Pan Chen, Linyong Xu, (unknown), Dan Wang, Daolin Tang, Liangchun Yang, Min Xie, Lizhi Cao, Minghua Yang	23
10	Polytropic Influence of TRIB3 rs2295490 Genetic Polymorphism on Response to Antihypertensive Agents in Patients With Essential Hypertension 2019 ·Frontiers in Pharmacology ·Jiecan Zhou, Fazhong He, Bao Sun, Rong Liu, Yongchao Gao, Huan Ren, Yan Shu, Xiaoping Chen, Zhaoqian Liu, Hong‐Hao Zhou, Sheng Deng, Heng Xu, Jianmin Li, Linyong Xu, Wei Zhang	8
11	[Epidemiological characteristics and spatial-temporal clustering analysis on pulmonary tuberculosis in Changsha from 2013 to 2016]. 2018 ·PubMed ·(unknown), Linyong Xu, Xiaojun Wang, (unknown), Lixin Song	6
12	[Sero-epidemiological survey on hepatitis B virus in Yunnan province, between 2006 and 2014]. 2017 ·PubMed ·(unknown), (unknown), (unknown), (unknown), Linyong Xu	1
13	PBX1 attributes as a determinant of connexin 32 downregulation inHelicobacter pylori-related gastric carcinogenesis 2017 ·World Journal of Gastroenterology ·Xiaoming Liu, Canxia Xu, (unknown), Lihua Huang, (unknown), Rong Li, (unknown), Linyong Xu, Ling Luo, Xiaoxia Jiang, Ming Li	9
14	Polymorphism of ORM1 Is Associated with the Pharmacokinetics of Telmisartan 2013 ·PLoS ONE ·(unknown), Yan Shu, Qing Li, Linyong Xu, Mary W Roederer, Lan Fan, Lanxiang Wu, Fazhong He, Jian‐Quan Luo, Zhi‐Rong Tan, Yijing He, Hong‐Hao Zhou, Xiang Chen, Wei Zhang	12
15	Propofol increases μ-opioid receptor expression in SH-SY5Y human neuroblastoma cells 2012 ·Molecular Medicine Reports ·Zuojun Li, Qi Pei, Jun‐Li Cao, Linyong Xu, Bikui Zhang, Shikun Liu	5
16	Association of plasma epinephrine level with insulin sensitivity in metabolically healthy but obese individuals 2011 ·Autonomic Neuroscience ·(unknown), Zhaoqian Liu, Linyong Xu, Zhicheng Gong, Qiong Huang, Min Dong, Xi Huang	8
17	Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism 2009 ·Clinica Chimica Acta ·Yijing He, Wei Zhang, Yao Chen, Dong Guo, Jianghua Tu, Linyong Xu, Zhi‐Rong Tan, Bi‐Lian Chen, Zhi Li, Gan Zhou, Bangning Yu, Julia Kirchheiner, Hong‐Hao Zhou	70
18	SLCO1B1 521T→C functional genetic polymorphism and lipid‐lowering efficacy of multiple‐dose pravastatin in Chinese coronary heart disease patients 2007 ·British Journal of Clinical Pharmacology ·Wei Zhang, Bi‐Lian Chen, Vural Özdemir, Yijing He, Gan Zhou, (unknown), Sheng Deng, (unknown), Wei Xie, Linyong Xu, (unknown), Lan Fan, An Wang, Hong‐Hao Zhou	58
19	OATP1B1 POLYMORPHISM IS A MAJOR DETERMINANT OF SERUM BILIRUBIN LEVEL BUT NOT ASSOCIATED WITH RIFAMPICIN‐MEDIATED BILIRUBIN ELEVATION 2007 ·Clinical and Experimental Pharmacology and Physiology ·Wei Zhang, Yijing He, Gan Zhou, Lan Fan, Qing Li, An Wang, Zhaoqian Liu, Sheng Deng, Yuanfei Huang, Linyong Xu, Hong‐Hao Zhou	64
20	Organic anion transporting polypeptide-1B1 haplotypes in Chinese patients 2007 ·Acta Pharmacologica Sinica ·Linyong Xu, Yijing He, Wei Zhang, Sheng Deng, Qing Li, Weixia Zhang, Zhaoqian Liu, Dan Wang, Yuanfei Huang, Hong‐Hao Zhou, Zhenqiu Sun	37

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact